Galderma Laboratories

Galderma is a leading global dermatology company that provides a comprehensive portfolio of premium brands across injectable aesthetics, therapeutic dermatology, and dermatological skincare. The company is well-known for iconic brands such as Cetaphil, Restylane, and Differin, catering to a wide range of skin health needs from acne and rosacea to skin aging. Galderma operates a sophisticated R&D engine, recently highlighted by the development of nemolizumab, a first-in-class monoclonal antibody for pruritic skin diseases. With a presence in over 90 countries, the company supports healthcare professionals and consumers through integrated skin health solutions. Following its 2024 IPO on the SIX Swiss Exchange, Galderma continues to expand its market leadership in the fast-growing dermatology sector.